| Expression pattern: |
UP |
| Associated gene: |
- |
| Associated microRNA: |
- |
| Biological function: |
Promotes leukemic cell proliferation and cell cycle progression, inhibits apoptosis, and is associated with disease progression in MDS and AML. |
| Molecular mechanism: |
Mechanism not fully defined; functional data indicate circZBTB46 enhances proliferation and cell cycle progression and reduces apoptosis in leukemic cells. |
| Biological pathway or process: |
proliferation (promotes); apoptosis (inhibits); cell cycle (promotes) |
| Detected method: |
Q
M
|
| Validation methods: |
Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; RT-qPCR; Microarray; Clinical Sample Validation; Nuclear-Cytoplasmic Fractionation; Transfection; CCK8; Annexin V/PI Flow Cytometry; Cell Cycle Assay; Cohort Study; Survival Analysis; Bioinformatics Analysis |
| Clinical significance: |
High circZBTB46 expression is associated with MDS risk stratification, AML transformation, AML treatment response, and shorter survival in MDS and AML patients. |
| Description: |
circZBTB46 is a human circRNA derived from ZBTB46 that is up-regulated in bone marrow samples from MDS and AML patients, with higher expression in higher-risk disease states. Clinically, high circZBTB46 expression is associated with adverse disease features, AML transformation, poorer treatment response in AML, and shorter survival. Functionally, circZBTB46 promotes leukemic cell proliferation and cell cycle progression while inhibiting apoptosis. |
| Confidence score: |
0.8196 |